![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA to Review Amgen’s First Biosimilar Candidate
FDA to Review Amgen’s First Biosimilar Candidate
![Amgen](https://www.fdanews.com/ext/resources/test/Drug-Images4/Amgen_logo.jpg?t=1614976958&width=430)
February 1, 2016
Amgen has cleared its first regulatory hurdle for biosimilar production with the FDA’s acceptance of its BLA for a biosimilar of the immunosuppressant Humira.
ABP 501 is the first of the company’s potential biosimilars that has made it this far, with two others currently undergoing pivotal trials. The BLA was submitted to the FDA in November following successful Phase 3 trials that “met their primary endpoints showing clinical equivalence” to AbbVie’s Humira, the company said.
The FDA set a Biosimilar User Fee Act (BsUFA) date of Sept. 25.
Upcoming Events
-
21Oct